Torrent Pharma Allots NCDs Worth ₹79,900 Crore Across Four Series
Torrent Pharmaceuticals Limited has allotted Non-Convertible Debentures (NCDs) worth ₹79,900 crore across four series on January 19, 2026. The NCDs range in tenure from 2 to nearly 5 years with annual coupon rates from 7.45% to 7.80%. The issuance was conducted via private placement and will be listed on NSE.
The substantial amount raised through NCD issuance (₹79,900 crore) is a material event for the company's capital structure and future financial flexibility.
The company successfully raised a significant amount of capital through the issuance of NCDs, which is generally viewed positively as it can support future growth and operations.
Torrent Pharmaceuticals Limited announced the allotment of Senior, Secured, Redeemable, Listed, Rated, Non-Convertible Debentures (NCDs) on January 19, 2026.
The Securities Transfer and Stakeholders Relationship Committee approved the allotment of Series 1 Debentures, comprising 2,00,000 NCDs with a nominal value of ₹100,000 each, aggregating to ₹20,000,000,000 (2000 crore). These debentures carry a coupon rate of 7.45% per annum and have a tenure of 2 years, maturing on January 19, 2028.
Series 2 Debentures, numbering 2,49,000 NCDs of ₹100,000 each, aggregate to ₹24,900,000,000 (2490 crore). These have a coupon rate of 7.60% per annum and a tenure of 3 years, maturing on January 19, 2029.
Series 3 Debentures consist of 3,00,000 NCDs of ₹100,000 each, aggregating to ₹30,000,000,000 (3000 crore). These carry a coupon rate of 7.70% per annum and have a tenure of 3 years, 11 months, and 30 days, maturing on January 18, 2030.
Series 4 Debentures comprise 3,50,000 NCDs of ₹100,000 each, aggregating to ₹35,000,000,000 (3500 crore). These NCDs have a coupon rate of 7.80% per annum and a tenure of 4 years, 11 months, and 29 days, maturing on January 17, 2031.
All NCDs are listed on the Wholesale Debt Market Segment of the National Stock Exchange of India Limited and will be redeemed at par. The issuance was done through private placement. The company has created a first-ranking exclusive charge over a designated account for NCD proceeds and specified trademarks to provide a minimum security cover of 1.1x.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.